Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

MLA

O’Reilly, Eileen M., et al. “Phase 1 Trial Evaluating Cisplatin, Gemcitabine, and Veliparib in 2 Patient Cohorts: Germline BRCA Mutation Carriers and Wild-Type BRCA Pancreatic Ductal Adenocarcinoma.” Cancer (0008543X), vol. 124, no. 7, Apr. 2018, pp. 1374–82. EBSCOhost, https://doi.org/10.1002/cncr.31218.

APA

O’Reilly, E. M., Lee, J. W., Lowery, M. A., Capanu, M., Stadler, Z. K., Moore, M. J., Dhani, N., Kindler, H. L., Estrella, H., Maynard, H., Golan, T., Segal, A., Salo, M. E. E., Yu, K. H., Epstein, A. S., Segal, M., Brenner, R., Do, R. K., Chen, A. P., & Tang, L. H. (2018). Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer (0008543X), 124(7), 1374–1382. https://doi.org/10.1002/cncr.31218

Chicago

O’Reilly, Eileen M., Jonathan W. Lee, Maeve A. Lowery, Marinela Capanu, Zsofia K. Stadler, Malcolm J. Moore, Neesha Dhani, et al. 2018. “Phase 1 Trial Evaluating Cisplatin, Gemcitabine, and Veliparib in 2 Patient Cohorts: Germline BRCA Mutation Carriers and Wild-Type BRCA Pancreatic Ductal Adenocarcinoma.” Cancer (0008543X) 124 (7): 1374–82. doi:10.1002/cncr.31218.